Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix Long-Term Safety Extension in Prostate Cancer
NCT00451958Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Mar 2007
- Primary completion
- Oct 2011
- Modality
- Peptides, Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label trial of degarelix in prostate cancer (PCa) (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight up to 4 years and Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables up to 4 years. Started Mar 2007; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00451958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451958.